GlassScriptPhysician profile
Caleb C Magistro
NPI 1366976987
$16,909.53
in general payments reported to CMS, 2019-2025
52 companies · $2,620 in 2025
The $2,620 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,222 · 2022: $2,730 · 2023: $3,451 · 2024: $6,886 · 2025: $2,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,367 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,730 · Travel and Lodging: $792 · Education: $68.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,367.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,730.00 |
| Travel and Lodging | $792.19 |
| Education | $68.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $4,789.48 | 2021-2025 | Delstrigo, Pifeltro, Dificid |
| Viiv Healthcare Company | $2,638.32 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $2,524.94 | 2021-2025 | |
| Novo Nordisk INC | $704.44 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $661.13 | 2021-2025 | |
| Janssen Biotech, INC. | $428.25 | 2021-2023 | Symtuza |
| Axsome Therapeutics, INC. | $411.03 | 2022-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $318.32 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $313.04 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Antares Pharma, INC. | $285.77 | 2021-2025 | Xyosted |
| Napo Pharmaceuticals INC | $283.17 | 2021-2025 | Mytesi |
| Astrazeneca Pharmaceuticals LP | $210.73 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Theratechnologies INC. | $197.52 | 2021-2025 | Trogarzo, Egrifta |
| Pfizer INC. | $189.06 | 2023-2025 | |
| Amgen INC. | $170.68 | 2021-2025 | Repatha, Otezla, Repatha |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $165.76 | 2023-2024 | Quviviq |
| Janssen Products, LP | $164.87 | 2021 | |
| Emd Serono, INC. | $164.72 | 2022-2025 | Serostim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.78 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Neos Therapeutics, LP | $156.05 | 2021-2023 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $148.79 | 2021-2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $134.84 | 2022 | |
| Abbott Laboratories | $122.67 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Tris Pharma INC | $115.66 | 2024 | Dyanavel Xr |
| Amarin Pharma, INC. | $114.49 | 2021-2022 | |
| Lundbeck LLC | $107.80 | 2022-2024 | Rexulti, Brintellix |
| Noven Therapeutics, LLC | $102.61 | 2023-2024 | Xelstrym |
| Glaxosmithkline, LLC. | $83.46 | 2022-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.74 | 2025 | Caplyta |
| Janssen Scientific Affairs, LLC | $77.03 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $71.49 | 2022 | |
| Halozyme INC | $70.18 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $65.31 | 2022 | |
| Currax Pharmaceuticals LLC | $64.15 | 2023-2025 | Nexletol, Contrave |
| Corium, LLC | $62.79 | 2024 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $54.76 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $54.07 | 2024-2025 | Fanapt |
| Acerus Pharmaceuticals Corporation | $50.15 | 2021-2022 | |
| Exact Sciences Corporation | $48.22 | 2024-2025 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $43.55 | 2025 | Azmiro |
| Phathom Pharmaceuticals, INC. | $43.25 | 2023-2024 | Voquezna |
| Bausch Health US, LLC | $40.20 | 2024 | Wellbutrin, Aplenzin |
| Sanofi-Aventis U.S. LLC | $35.38 | 2021-2022 | |
| Tolmar, INC. | $32.29 | 2023-2025 | Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $24.27 | 2025 | |
| Hologic Sales and Service, LLC | $23.98 | 2024 | Aptima |
| Aytu Biopharma, INC. | $20.96 | 2021 | |
| Astellas Pharma US INC | $19.82 | 2023 | Veozah |
| Clarus Therapeutics INC. | $15.53 | 2021 | |
| Esperion Therapeutics, INC. | $15.00 | 2024 | Nexletol |
| Supernus Pharmaceuticals, INC. | $14.13 | 2025 | Xyosted, Qelbree |
| Dexcom, INC. | $13.90 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Magistro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.